{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:35:08Z","timestamp":1794270908662,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.urolonc.2026.04.291","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:29:09Z","timestamp":1779362949000},"page":"372-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-7565","authenticated-orcid":false,"given":"Juan C.","family":"Angulo-Lozano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Posada-Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon Malik","family":"Wahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Suzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Iranmahboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Calvillo-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Merghoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parwiz","family":"Abrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.04.291_bib0001","unstructured":"NIH NCI Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. (Accessed October 21, 2025)"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0002","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of Bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0004","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: bladder cancer. 2025. https:\/\/wwwNccnOrg\/2025. (Accessed Otober 21, 2025)"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0006","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/1078-0432.CCR-22-3642","article-title":"A phase II trial of guadecitabine plus atezolizumab in metastatic urothelial carcinoma progressing after initial immune checkpoint inhibitor therapy","volume":"29","author":"Jang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0007","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0008","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of Durvalumab in locally advanced or metastatic urothelial carcinoma","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0010","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 Phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0013","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0015","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.24.00576","article-title":"First results of NURE-combo: a phase II study of neoadjuvant nivolumab and nab-paclitaxel, followed by postsurgical adjuvant nivolumab, for muscle-invasive bladder cancer","volume":"42","author":"Mercinelli","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0016","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0017","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0018","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0019","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0020","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.euo.2023.06.005","article-title":"Downstaging and survival associated with neoadjuvant immunotherapy before radical cystectomy for muscle-invasive bladder cancer","volume":"7","author":"Grassauer","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0022","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.trecan.2023.09.006","article-title":"The tumor-draining lymph node as a reservoir for systemic immune surveillance","volume":"10","author":"Delclaux","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to Adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0026","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ccell.2024.05.015","article-title":"Let it be: preserving tumor-draining lymph nodes in the era of immuno-oncology","volume":"42","author":"Saddawi-Konefka","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0027","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1038\/s41467-022-31941-w","article-title":"Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC","volume":"13","author":"Saddawi-Konefka","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0028","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0029","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306782120","article-title":"IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer","volume":"120","author":"Wong","year":"2023","journal-title":"Proceed Natl Acad Sci"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0030","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.4049\/jimmunol.1100670","article-title":"FTY720 Blocks egress of T cells in part by abrogation of their adhesion on the lymph node sinus","volume":"187","author":"Zhi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0031","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2567.1998.00639.x","article-title":"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T\u2003cells in Peyer\u2019s patches by FTY720-induced lymphocyte homing","volume":"95","author":"Yanagawa","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0032","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/intimm\/dxm091","article-title":"Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs","volume":"19","author":"Wong","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0033","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jncc.2022.10.002","article-title":"Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer","volume":"2","author":"Wang","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0034","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/jcm12072636","article-title":"Updated immunotherapy for gastric cancer","volume":"12","author":"Narita","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jim.2007.11.012","article-title":"Lymph node mapping in the mouse","volume":"332","author":"Harrell","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0036","article-title":"T cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0037","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110331","article-title":"PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes","volume":"38","author":"Nagasaki","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0039","article-title":"Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.04.291_bib0040","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2023.41.16_suppl.4508","article-title":"SWOG S1011: a phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer","volume":"41","author":"Lerner","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:20:19Z","timestamp":1783192819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1078143926005016"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.291","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}